Annual Results 2014

VALNEVA SE, Lyon

March 20, 2015

VALNEVA SE
Gerland Plaza Techsud
70, rue Saint Jean de Dieu
69007 – Lyon, France
www.valneva.com

valneva

VALNEVA REPORTS ANNUAL RESULTS 2014

The company announces a significant improvement to its EBITDA and a strong reduction of its net loss compared to prior-year pro forma result

+ Significant progress on building a financially sustainable business, EBITDA improvement of 63.9%, Net loss improvement of 32.5% compared to 2013 on pro forma basis
+ 2014 Revenues through marketed products of EUR 28.1 million expected to be substantially increased in 2015 by acquired second commercialized vaccine Dukoral®
+ Valneva's key phase II and II/III clinical programs are proceeding towards important value inflection points towards the end of 2015
+ Active progression on licensing activity for vaccines produced in EB66® underpinned by recent announcements

Outlook

+ The Company expects its 2015 revenues to be significantly increased to between approximately EUR 75 and 85 million by its recent acquisition of the Dukoral® vaccine including a Nordic vaccine sales infrastructure and by revenue growth in its historical activities (revenue includes Dukoral® product sales by the seller's group entities under transitional service agreement)
+ Revenues of IXIARO® product sales are expected to grow to approximately EUR 30 million
+ Valneva expects to continue to strive towards break-even following the transitional period of 2015 and the integration of the recently acquired business (2015 results may be significantly impacted by non-cash effects from acquisition accounting)
+ Within the next twelve months, Valneva expects important clinical results from its Pseudomonas aeruginosa vaccine phase II/III and its Clostridium difficile vaccine phase II studies which both have the potential to transform the value of the Company

MARCH 20, 2015

valneva

Key Financial Information (audited)

EUR IN THOUSANDS	3 MONTHS ENDED DEC 31,		12 MONTHS ENDED DEC 31,		
	2014	*2013*	*2014*	*2013*	*2013 pro forma*
Revenues & Grants	13,113	11,640	42,429	35,991	43,684
Net profit/(loss)	(11,520)	(6,028)	(26,272)	(24,110)	(38,902)
EBITDA	(3,754)	(1,273)	(7,364)	(11,709)	(20,402)
Net operating cash flow	(7,846)	1,131	(14,944)	(20,903)	n/a
Cash, short-term deposits and marketable securities, end of period	29,468	40,167	29,468	40,167	40,167

Lyon (France), March 20, 2015 – Valneva SE ("Valneva"), a leading pure-play vaccines biotech company, today published its audited full year financial results for the period ended December 31, 2014 (as reviewed by the Supervisory Board on March 19, 2015), a summary of its operational achievements in 2014 and its 2015 business outlook. The full consolidated financial statements 2014 are available on the Company's website www.valneva.com.

A webcast for financial analysts, fund managers, investors and journalists will be held today at 2:00pm (CET). Link: http://edge.media-server.com/m/p/am8qidik. A replay will be available after the webcast on the Company's website.

Thomas Lingelbach, President and Chief Executive Officer and Franck Grimaud, President and Chief Business Officer of Valneva, commented, "2014 was a successful year for Valneva on its way to further building a leading pure-play vaccines biotech company according to our strategy to seek financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.We are looking forward to an exciting year 2015 with increased revenues and upcoming important data points in our clinical programs."

Business Highlights

CORPORATE NEWS

+ *Valneva becomes a leading pure-play vaccines biotech company through the Dukoral® Vaccine acquisition and the creation of BliNK Biomedical*

In February 2015, the Company completed the acquisition of Crucell Sweden AB, including the Nordics vaccine distribution business and all assets, licenses and privileges related to Dukoral®, a vaccine against cholera and traveler's diarrhea caused by ETEC. The acquisition included the purchase of a manufacturing site in Solna (Sweden). The acquired business generated revenues of EUR 37.9 million in 2013 and EUR 36.4 million in 2014 from the sales of the Dukoral® vaccine and the distribution of several other vaccines for third parties.

In January 2015, Valneva and British company BliNK Therapeutics Ltd created a private company, Blink Biomedical SAS, specialized in the discovery of innovative monoclonal antibodies. Valneva contributed its VIVA|Screen® antibody technology to the new business. This step allows Valneva to concentrate on vaccines research, development and commercialization, while continuing to benefit from its VIVA|Screen® antibody technology through the new company.

+ *GSK becomes Valneva's key strategic partner in vaccines by completing its acquisition of Novartis' vaccine business*

On March 2, 2015 GlaxoSmithKline (GSK) and Novartis announced that their three-part transaction which includes the acquisition of Novartis' global vaccines business (excluding influenza vaccines) has been completed. Valneva's partnership with Novartis on the distribution of IXIARO®, the programs under its Strategic Alliance Agreement with Novartis, including Valneva's late stage Pseudomonas and C. difficile vaccines, and Novartis' shareholding in Valneva of approximately 3.0 million ordinary shares and 2.7 million preferred shares have now transitioned to GSK.

The Company has entered into a detailed dialogue with GSK regarding the various aspects of its new strategic relationship.

MARKETED PRODUCT

+ *IXIARO®/JESPECT®*

IXIARO®/JESPECT® product sales were EUR 28.1 million in 2014 compared to EUR 27.2 million pro-forma product sales in 2013, representing a 3.4% year-on-year growth, mainly driven by growth in the travel markets and supplies to the U.S. military. Sales also benefited from favorable currency exchange rates.

After adjusting for the change in revenue recognition resulting from the transition of the U.S. military sales responsibility to Novartis, 2014 product sales represented a 14.0% year-on-year growth compared to 2013 pro-forma product sales. The transition of the U.S. military sales responsibility to Novartis resulted in Valneva now recognizing only two thirds of the total sales revenue to the U.S. military instead of 100 % previously

In April 2014, Valneva granted vaccine manufacturer Adimmune Corporation rights to register and commercialize its JE vaccine under a local trade name in Taiwan. Under the terms of the agreement, Valneva will supply intermediate-stage bulk product while Adimmune will be responsible for final release and commercialization of the product.

In the past year Valneva also recorded the first revenues from royalties on Biological E.'s sales of Japanese encephalitis vaccines (JEV) in India under the trade name JEEV. Valneva expects the royalties on Biological E.'s sales to increase progressively, especially as the vaccine has been prequalified by the World Health Organization (WHO) – a key step for distribution of the vaccine in developing countries.

The Company anticipates its strong disease awareness and promotional efforts to lead to continued double-digit in-market sales growth and revenues to Valneva of approximately EUR 30 million in 2015. Through the new agreement with Adimmune, increasing revenues from royalties on Biological E.'s JEV sales in India, and the changes to the Company's main marketing & distribution agreement, Valneva expects significant improvement in the profitability of its commercial product franchise going forward.

R&D PROGRAMS

+ *Pseudomonas aeruginosa: Recruitment of patients for phase II/III continuation progressing according to plan. Preliminary results expected at the end of 2015 early 2016*

The enrolment of further patients in the phase II/III pivotal efficacy trial for which the group announced the continuation following an interim analysis at the end of March 2014 is progressing according to plan. In addition to the 394 patients already enrolled in the study, the Company has started the recruitment of another 400 ventilated intensive care patients in 40 different sites. Valneva is also considering the option to extend the study further. Preliminary decisions / results are expected at the end of 2015 / early 2016.

Valneva estimates that the up to one million intensive care unit patients on mechanical ventilation in the U.S. and Europe annually could represent a potential target population for the vaccine.

+ *Clostridium difficile Vaccine Candidate: Phase II data expected at end of 2015*

In December 2014, Valneva initiated the phase II clinical trial of its VLA84 prophylactic vaccine candidate against Clostridium difficile (C. difficile).

The phase II study (VLA84-201) has enrolled 500 healthy subjects aged 50 years and older. This age group represents the target population for a prophylactic C. difficile vaccine as the risk to contract the infection-associated disease increases with age. The randomized, placebo-controlled, observer-blind study is being conducted in Germany as well as in the United States under an Investigational New Drug application (IND).

The phase II study aims to confirm the optimal dose and formulation of the vaccine in two different age groups and to generate sufficient additional clinical data to advance the program into Phase III. Data are expected to be reported by the end of this year.

+ *Borrelia (lyme disease): Pre-clinical development completed, decision on next development steps in 2015*

Valneva has developed a multivalent, protein subunit based vaccine candidate. This candidate has completed pre-clinical development and is currently in the pre-IND-process including regulatory advice (ongoing) and consultation processes (completed).

In November 2014, the preclinical data of Valneva's novel vaccine candidate for prevention of Lyme borreliosis, were published in PLOS ONE, the largest scientific journal in the world by volume.

The article entitled: "Design and development of a novel vaccine for protection against Lyme borreliosis" details for the first time Valneva´s Borrelia/Lyme borreliosis vaccine approach, with design, proof-of-concept studies and preclinical data on protection.

The publication reveals that Valneva's vaccine candidate, a multivalent, protein subunit based vaccine, has the potential to provide protection against the majority of Borrelia species pathogenic for humans. Lyme borreliosis is caused by at least four species of Borrelia and is transmitted via the bite of an infected tick. Delayed or inadequate treatment can lead to very serious symptoms, involving the joints, heart, and central nervous system, which can be disabling.

Valneva expects to announce a decision on timing for clinical development entry in 2015.

TECHNOLOGIES & SERVICES

+ *EB66® cell line: significant milestones in 2014*

› First EB66®-based human vaccine approved and first approval in Europe

In March 2014, the first ever marketing authorization for a human vaccine produced in EB66® cell line was granted to the Chemo-Sero Therapeutic Research Institute (Kaketsuken), a co-development partner to GlaxoSmithKline (GSK). Kaketsuken received the marketing authorization in Japan for a pandemic H5N1 influenza vaccine produced in Valneva's EB66® cell line. The vaccine has been developed in accordance to the Japanese government's plan to rapidly

respond to an influenza pandemic both before and during an outbreak, and has been approved for prophylaxis of pandemic H5N1 influenza.

In March 2014, Valneva also announced the approval and launch of another veterinary vaccine produced in the EB66® cell line in South America. The vaccine for the prevention of inclusion body hepatitis virus was developed by Lima (Peru) based biopharmaceutical company FARVET SAC, and will be available for sale in Peru and several other South American countries.

In May 2014, announced the first marketing approval in Europe for a vaccine produced in the EB66® cell line. The marketing authorization was granted by the European Medicines Agency (EMA) for the prevention of Muscovy Duck Parvovirus (MDPV). This approval was an important milestone for Valneva as the EMA has now validated the use of the EB66® cell line in vaccines. Valneva licensed the marketing of the MDPV product to Merial. First revenues of product sales are expected from 2015 onwards.

› Inauguration of EB66®-based Influenza Facility in Texas (GSK)

In September 2014, Valneva joined GlaxoSmithKline (GSK) in celebrating the site dedication of the Texas A&M Pandemic Influenza Vaccine Facility in Texas, which is on track for completion of construction by the end of 2015, to be followed by start-up phase in 2016. This new facility will provide the capabilities to manufacture bulk antigen for GSK's next generation pandemic influenza vaccine, based on Valneva's proprietary EB66® cell line, to help protect the United States against global influenza pandemics.

› New license agreements in 2014

In March 2014, Valneva signed a new research license agreement and transferred an existing commercial agreement to Emergent BioSolutions Inc. (NYSE:EBS), to develop new vaccines using Valneva's EB66® cell line.

In August 2014, Valneva signed a clinical development license agreement with the US firm GeoVax Labs, Inc. (OTCQB: GOVX), to develop MVA-based vaccines in Valneva's EB66® vaccine production cell line. The deal broadened the collaboration between the two companies which have been working together since 2008 to generate a process for manufacturing the MVA component of GeoVax's HIV/AIDS combination vaccine using Valneva's EB66® cell line technology.

In November 2014, Valneva signed two new research agreements in Japan to develop human and veterinary vaccines in Valneva's EB66® cell line.

› Outlook, Events in 2015

Valneva expects continued momentum in the signing of new EB66® license agreements in 2015 as evidenced by the recently announced exclusive license agreement with Chinese company Jianshun Biosciences Ltd to commercialize Valneva's EB66® cell line for the manufacturing of human and veterinary vaccines in People's Republic of China as well as the signing of two new veterinary licenses in Europe, with Merial and another undisclosed company.

+ *IC31® adjuvant: Tuberculosis Vaccine candidate formulated with IC31® showed good safety and immunogenicity in phase II*

Valneva has granted multiple licenses (to Novartis and Statens Serum Institut – SSI, among others) to evaluate IC31® in new vaccine formulations in infectious disease.

In the field of tuberculosis, three clinical vaccine candidates, all formulated with Valneva´s IC31® adjuvant, are currently being tested in phase I and II clinical trials as part of the Company's agreement with SSI and their partners, including Aeras and Sanofi Pasteur.

In March 2014 Aeras initiated a Phase II randomized clinical trial for their tuberculosis vaccine candidate Aeras-404 using Valneva's IC31® proprietary adjuvant.

In December 2014, Valneva announced that the Statens Serum Institut's novel Tuberculosis vaccine candidate H1/IC31® formulated with Valneva's proprietary adjuvant IC31® showed good safety and immunogenicity in Phase II clinical trial in HIV-infected adults.

At the beginning of 2015, Valneva announced the signing of an exclusive worldwide commercial license agreement with Immune Targeting Systems (ITS) Ltd. The agreement grants ITS the rights to research, develop and commercialize Hepatitis B vaccine candidates in combination with Valneva's IC31® adjuvant.

FINANCIAL REVIEW

Note: As a result of the merger between Vivalis SA and Intercell AG, Intercell's business has been included in the Group's consolidated financial statements from the merger closing date May 28, 2013. Therefore, the 2014 and 2013 IFRS results are not fully comparable as the ex-Intercell operations were only included for the period 2013 starting from June 2013. Pro-forma figures including the Intercell business for the 2013 period and excluding one-time effects due to the merger were prepared for illustrative purposes only. For detailed explanation of pro-forma assumptions and reconciliation to IFRS results, please refer to note 32 of the Consolidated Financial Statements 2014 (www.valneva.com).

REVENUES AND GRANTS

Valneva's aggregate revenues and grants increased from EUR 36.0 million in the year 2013 to EUR 42.4 million in the year 2014. This increase was mainly due to the contribution of ex-Intercell revenues to the business as a result of the merger of Vivalis and Intercell to form Valneva. Compared to the previous year on a pro forma basis (combining Intercell's revenues and grants in the first five months of 2013 with Valneva's revenues and grants since June) revenues and grants slightly decreased from EUR 43.7 million in 2013 to EUR 42.4 million in 2014. This decrease was mainly due to a decrease in revenues from collaborations and licensing.

IXIARO®/JESPECT® product sales contributed EUR 28.1 million to revenues in 2014. On a pro-forma basis full year 2013 product sales were EUR 27.2 million representing an increase of 3.4% in 2014 despite the transition in the U.S. military sales responsibility to Novartis from late 2013 onward which resulted in Valneva now recognizing only two thirds of the total sales revenue to the U.S. military instead of 100% previously.

Revenues from collaborations and licensing increased from EUR 7.2 million in 2013 to EUR 8.8 million in 2014. On pro forma basis revenues from collaborations and licensing decreased from EUR 10.8 million in 2013 to EUR 8.8 million in the full year 2014 due to a decrease in revenues from EB66® cell line technology from EUR 3.7 million in the year 2013 to EUR 2.3 million in the year 2014 and a decrease in revenues from the VivaIScreen® antibody platform from EUR 2.9 million in the year 2013 to EUR 1.7 million in the year 2014.

Grant income amounted to EUR 5.5 million in 2014 and was flat compared to 2013. On a pro forma basis grant income was EUR 5.7 million in the year 2013.

OPERATING RESULT AND EBITDA

The operating loss increased from EUR 20.9 million in 2013 to EUR 23.8 million in 2014. On a pro forma basis, the operating loss decreased by EUR 8.7 million, or 26.8%, from EUR 32.5 million in the year 2013 to EUR 23.8 million in the year 2014. This decrease was mainly due to cost synergies and prioritization of R&D activities in connection with the merger, including savings as a result of the disposal of the CMO business in the fourth quarter 2013.

Cost of goods and services increased by EUR 0.6 million from EUR 16.5 million in the year ended 2013 to EUR 17.1 million in the year 2014. The gross margin on the Japanese Encephalitis product

improved from 29.0% in 2013 to 44.7% in the full year 2014. On a pro forma basis cost of goods and services decreased by EUR 2.9 million from EUR 20.0 million in the full year 2013 to EUR 17.1 million in the year 2014.

Research and Development expenses ("R&D") increased by EUR 0.8 million from EUR 21.4 million in the year ended 2013 to EUR 22.2 million in the year 2014. On a pro forma basis R&D expenses decreased by EUR 8.5 million. This decrease resulted from R&D pipeline prioritization and cost synergies, implemented as part of the merger integration, as well as timing effects in connection with clinical trial costs and savings as a result of the disposal of the CMO business in the fourth quarter 2013.

General, selling and administrative expenses ("SG&A") decreased slightly from EUR 14.7 million in the year 2013 to EUR 14.1 million in the year 2014. On a pro forma basis SG&A expenses decreased by 32.0% from EUR 20.8 million in the year 2013. The transition of the U.S. military sales responsibility to Novartis contributed significantly to the reduction of selling expenses in 2014 in comparison to 2013.

Net other operating income changed from EUR 1.2 million in the year 2013 to a net other operating expense of EUR 0.4 million in 2014. This change was mainly due to the prior year effect of a gain from the sale of the CMO business in 2013.

Amortization and impairment charges increased by EUR 7.0 million from EUR 5.4 million in the year 2013 to EUR 12.3 million in the year 2014. In 2014 an impairment charge of EUR 4.1 million in connection with the antibody business was recognized as the Company decided to change the strategy on the antibody business.

Valneva's EBITDA improved to minus EUR 7.4 million in the year 2014 from minus EUR 11.7 million in year 2013. On a pro-forma basis, the 2014 EBITDA improvement was 63.9% compared minus EUR 20.4 million in the same period of the previous year. EBITDA was calculated by excluding depreciation, amortization and impairment from the operating loss recorded in the condensed consolidated income statement under IFRS.

NET RESULT

Valneva's net loss in the year 2014 was EUR 26.3 million compared to EUR 24.1 million for the same period of the previous year. On a pro-forma basis, the net loss decreased by 32.5% to EUR 26.3 million in the year 2014 from EUR 38.9 million in year 2013. The decrease reflects the progress made in both, the merger consolidation and the cost saving projects.

CASH FLOW AND LIQUIDITY

Net cash used in operating activities decreased by EUR 6.0 million from EUR 20.9 million in the year 2013 to EUR 14.9 million in the year 2014. This decrease reflects the financial progress in cash-flow relevant operating expenses, whereas non-cash expenses such as depreciation, amortization and impairment charges have increased.

Cash in-flows from investing activities changed by EUR 19.9 million, or 90.1%, to EUR 2.0 million in the year 2014 from EUR 21.9 million in the year 2013. The change resulted primarily from proceeds/purchases of financial assets as well as cash acquired in the acquisition of other businesses. In the year 2013, EUR 11.6 million was cash acquired from acquisitions and EUR 10.0 million was net proceeds from sale of financial assets, while proceeds (net of purchases) of financial assets amounted to EUR 3.5 million in the year 2014. The purchases of intangible assets and property, plant and equipment (net of proceeds from sale of such assets) amounted to EUR 2.0 million in the year 2014 and to EUR 0.1 million in the year 2013.

Cash in-flows from financing activities were EUR 5.3 million in the year 2014 and EUR 34.7 million in the year 2013. In the year 2014, net cash generated from financing activities resulted primarily from a capital increase through the Company's equity line, which was partially offset by repayments of borrowings. In the year 2013, net cash generated from financing activities resulted primarily from the net proceeds of a capital increase completed in July 2013.

CASH POSITION AT YEAR-END

Liquid funds at December 31, 2014 stood at EUR 29.5 million compared to EUR 40.2 million at the end of December 2013 and consisted of EUR 28.9 million cash and EUR 0.6 million restricted cash.

+ *Contacts:*

Valneva SE
Teresa Pinzolits
T +43-1-206 20-1116
Communications@valneva.com

Florence Hocdee-Leroy
T: +33 (0)228 07 37 10

+ *About Valneva SE*

Formed in 2013 through the merger of Intercell AG and Vivalis SA, Valneva is a biotechnology company developing, manufacturing and commercializing innovative vaccines with a vision to protect people from infectious diseases. The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability. Valneva´s portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese encephalitis (IXIARO®) and the second (Dukoral®) indicated for the prevention of and protection against traveler's diarrhea caused by ETEC (Enterotoxigenic Escherichia coli) and/or Cholera. The Company has proprietary vaccines in development including candidates against Pseudomonas aeruginosa, Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company's value proposition and include vaccines being developed using Valneva´s innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant). Valneva is headquartered in Lyon, France, listed on Euronext-Paris and the Vienna stock exchange and operates out of France, Austria, Scotland and Sweden with approximately 400 employees. More information is available at www.valneva.com.

+ *Forward-Looking Statements*

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing and completion of research, development and clinical trials for product candidates, the ability to manufacture, market, commercialize and achieve market acceptance for product candidates, the ability to protect intellectual property and operate the business without infringing on the intellectual property rights of others, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements and needs for additional financing. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing the information in these materials as of the date of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONSOLIDATED INCOME STATEMENT (AUDITED)

EUR IN THOUSANDS (EXCEPT PER SHARE AMOUNTS)	THREE MONTHS ENDED DECEMBER 31		YEAR ENDED DECEMBER 31,	
	2014	*2013*	*2014*	*2013*
Product sales	8,842	6,542	28,124	23,239
Revenues from collaborations, licensing and services	2,653	2,335	8,799	7,206
Revenues	**11,495**	**8,878**	**36,922**	**30,445**
Grant income	1,618	2,762	5,506	5,546
Revenues and grants	**13,113**	**11,640**	**42,429**	**35,991**
Cost of goods and services	(6,994)	(6,327)	(17,144)	(16,508)
Research and development expenses	(7,022)	(6,582)	(22,242)	(21,423)
General, selling and administrative expenses	(3,916)	(2,597)	(14,142)	(14,720)
Other income and expenses, net	(154)	1,291	(395)	1,157
Amortization and impairment	(4,877)	(2,012)	(12,323)	(5,353)
OPERATING LOSS	**(9,851)**	**(4,588)**	**(23,817)**	**(20,856)**
Finance income	300	8	2,273	200
Finance expenses	(1,977)	(977)	(4,394)	(2,969)
LOSS BEFORE INCOME TAX	**(11,528)**	**(5,573)**	**(25,938)**	**(23,625)**
Income tax	8	(319)	(334)	(348)
LOSS FROM CONTINUING OPERATIONS	**(11,520)**	**(5,892)**	**(26,272)**	**(23,973)**
Loss from discontinued operations	-	(137)	-	(137)
LOSS FOR THE PERIOD	**(11,520)**	**(6,028)**	**(26,272)**	**(24,110)**
Losses per share *for loss from continuing operations attributable to the equity holders of the Company, expressed in EUR per share (basic and diluted)*	(0.21)	(0.11)	(0.47)	(0.61)

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (AUDITED)

EUR IN THOUSANDS	YEAR ENDED DECEMBER 31,	
	2014	*2013*
Loss for the year	**(26,272)**	**(24,110)**
Other comprehensive income/(loss)		
Items that are or may be reclassified subsequently to profit or loss		
Currency translation differences	(2,626)	1,636
Total items that are or may be reclassified subsequently to profit or loss	**(2,626)**	**1,636**
Other comprehensive income/(loss) for the year, net of tax	**(2,626)**	**1,636**
TOTAL COMPREHENSIVE LOSS FOR THE YEAR ATTRIBUTABLE TO THE OWNERS OF THE COMPANY	**(28,897)**	**(22,474)**

CONSOLIDATED BALANCE SHEET (AUDITED)

EUR IN THOUSANDS	AT DECEMBER 31,	
	2014	*2013*
ASSETS		
Non-current assets	**166,567**	**191,045**
Intangible assets and goodwill	105,204	125,403
Property, plant and equipment	41,611	45,067
Other non-current assets	19,753	20,575
Current assets	**52,967**	**63,346**
Inventories	7,282	4,819
Trade receivables	6,850	7,570
Other current assets	9,366	10,791
Current financial assets	19	3,658
Cash and cash equivalents and short-term deposits	29,449	36,509
Assets held for sale	**7,982**	**-**
TOTAL ASSETS	**227,517**	**254,391**
EQUITY		
Capital and reserves attributable to the Company's equity holders	**124,444**	**144,111**
Share capital	8,453	8,206
Share premium and other regulated reserves	206,707	198,322
Retained earnings and other reserves	(64,444)	(38,308)
Net result for the period	(26,272)	(24,110)
LIABILITIES		
Non-current liabilities	**75,704**	**82,181**
Borrowings	66,036	64,902
Other non-current liabilities and provisions	9,668	17,279
Current liabilities	**26,387**	**28,100**
Borrowings	7,117	6,381
Trade payables and accruals	11,009	11,388
Tax and employee-related liabilities	5,398	5,096
Other current liabilities and provisions	2,862	5,235
Liabilities held for sale	**982**	**-**
TOTAL LIABILITIES	**103,073**	**110,280**
TOTAL EQUITY AND LIABILITIES	**227,517**	**254,391**

CONSOLIDATED CASH FLOW STATEMENT (AUDITED)

EUR IN THOUSANDS	YEAR ENDED DECEMBER 31,	
	2014	*2013*
CASH FLOWS FROM OPERATING ACTIVITIES		
Loss for the year	(26,272)	(24,110)
Depreciation and amortization	12,359	9,056
Impairment	4,095	92
Share-based payments	530	179
Income tax	334	348
Other adjustments for reconciliation to cash used in operations	(2,439)	(1,739)
Changes in working capital	(938)	(3,311)
Cash used in operations	**(12,332)**	**(19,485)**
Interest paid	(2,227)	(1,121)
Income tax paid	(385)	(296)
Net cash used in operating activities	**(14,944)**	**(20,903)**
CASH FLOWS FROM INVESTING ACTIVITIES		
Acquisition of other businesses, net cash acquired	-	11,615
Purchases of property, plant and equipment	(946)	(1,375)
Proceeds from sale of property, plant and equipment	1,712	3,144
Purchases of intangible assets	(2,792)	(1,899)
Purchases of financial assets	(13,616)	-
Proceeds from sale of financial assets	17,130	10,037
Interest received	505	332
Net cash generated from investing activities	**1,993**	**21,855**
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issuance of common stock, net of costs of equity transactions	8,632	37,621
Disposal/(Purchase) of treasury shares	69	(684)
Proceeds from borrowings	1,656	27,646
Repayment of borrowings	(5,083)	(29,893)
Net cash generated from financing activities	**5,274**	**34,689**
Net change in cash and cash equivalents	**(7,677)**	**35,641**
Cash at beginning of the year	36,509	832
Exchange gains/(losses) on cash	25	36
Cash at end of the year	**28,857**	**36,509**
Cash, cash equivalents, and financial assets at end of the year	**29,468**	**40,167**